Barclays PLC Has $14.13 Million Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Barclays PLC increased its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 51.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 263,970 shares of the company's stock after acquiring an additional 89,909 shares during the period. Barclays PLC owned about 0.50% of Janux Therapeutics worth $14,133,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. FMR LLC grew its position in Janux Therapeutics by 10.8% in the fourth quarter. FMR LLC now owns 8,669,941 shares of the company's stock valued at $464,189,000 after acquiring an additional 845,266 shares during the period. Wellington Management Group LLP grew its holdings in shares of Janux Therapeutics by 3,592.9% in the 4th quarter. Wellington Management Group LLP now owns 535,396 shares of the company's stock worth $28,665,000 after purchasing an additional 520,898 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Janux Therapeutics by 2,519.6% during the 4th quarter. Franklin Resources Inc. now owns 497,287 shares of the company's stock worth $26,625,000 after purchasing an additional 478,304 shares in the last quarter. Pictet Asset Management Holding SA acquired a new stake in shares of Janux Therapeutics during the 4th quarter worth about $20,602,000. Finally, Vanguard Group Inc. lifted its holdings in Janux Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 2,136,332 shares of the company's stock valued at $114,379,000 after purchasing an additional 288,402 shares during the last quarter. Institutional investors own 75.39% of the company's stock.

Insider Activity

In related news, Director Ra Capital Management, L.P. bought 110,206 shares of the company's stock in a transaction on Friday, March 7th. The shares were purchased at an average cost of $31.02 per share, for a total transaction of $3,418,590.12. Following the acquisition, the director now owns 10,141,287 shares of the company's stock, valued at approximately $314,582,722.74. This represents a 1.10 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $32.15, for a total transaction of $107,188.10. Following the completion of the transaction, the insider now owns 82,139 shares of the company's stock, valued at $2,640,768.85. This trade represents a 3.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,002 shares of company stock valued at $348,203 in the last ninety days. 29.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

JANX has been the subject of a number of research analyst reports. Scotiabank cut their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research note on Friday, February 28th. William Blair reiterated an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Lifesci Capital upgraded Janux Therapeutics to a "strong-buy" rating in a report on Friday, December 27th. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 price target on shares of Janux Therapeutics in a report on Monday, March 3rd. Finally, Wedbush reissued an "outperform" rating and set a $76.00 price objective (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $95.25.

Janux Therapeutics Trading Down 4.8 %

Shares of NASDAQ:JANX traded down $1.56 during trading on Friday, hitting $30.52. 118,467 shares of the company's stock were exchanged, compared to its average volume of 849,512. The firm has a market cap of $1.80 billion, a P/E ratio of -25.97 and a beta of 3.27. The firm has a 50-day moving average price of $30.20 and a two-hundred day moving average price of $43.23. Janux Therapeutics, Inc. has a 1-year low of $22.52 and a 1-year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, research analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.